摘要
目的探讨雷珠单抗玻璃体腔注射配合玻璃体切割术治疗玻璃体积血(vitreous hemorrhage,VH)的临床效果。方法选取2022年4月—2023年5月丹江口市第一医院收治的86例(102眼)VH患者为研究对象,根据不同治疗方法分为对照组与观察组,每组43例(51眼)。对照组予以玻璃体切割术治疗,观察组在对照组基础上加用雷珠单抗玻璃体腔注射。比较2组的临床疗效、炎症指标水平、最佳矫正视力、生活质量及并发症发生情况。结果观察组的临床总有效率为93.02%,高于对照组的76.74%,差异有统计学意义(P<0.05)。治疗后,观察组的超敏-C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、血管内皮生长因子(vascular endothelial growth factor,VEGF)、白细胞介素-6(interleukin-6,IL-6)水平分别为(6.05±0.09)mg/L、(35.04±7.44)ng/L、(4.32±0.95)pg/mL,低于对照组的(7.33±0.12)mg/L、(48.55±9.68)ng/L、(5.48±1.03)pg/mL,差异均有统计学意义(P<0.05)。观察组的最佳矫正视力为(0.49±0.09),高于对照组的(0.34±0.06),差异有统计学意义(P<0.05)。观察组世界卫生组织生存质量测定量表(the World Health Organization quality of life scale-brief form questionnaire,WHOQOL-BREF)评估结果中,心理领域、生理领域、环境领域、社会关系领域评分分别为(81.55±6.98)分、(70.12±6.12)分、(75.41±7.84)分、(80.56±6.42)分,高于对照组的(72.39±5.47)分、(58.34±5.66)分、(64.93±5.99)分、(71.55±5.37)分,差异均有统计学意义(P<0.05)。观察组并发症发生率为4.65%,低于对照组的20.93%,差异有统计学意义(<0.05)。结论雷珠单抗玻璃体腔注射配合玻璃体切割术治疗VH的效果确切,可改善最佳矫正视力,减轻炎症反应,减少并发症的发生,提高生活质量,此文的研究结果为VH后期规范化治疗方案的制订提供了借鉴。
Objective To investigate the clinical effect of intravitreal injection of ranibizumab combined with vitrectomy on patients with vitreous hemorrhage(VH).Methods A total of 86 cases(102 eyes)of VH patients admitted to Danjiangkou First Hospital from April 2022 to May 2023 were selected as the research subjects.They were divided into a control group and an observation group according to different treatment methods,with 43 cases(51 eyes)in each group.The control group received vitrectomy treatment,while the observation group received intravitreal injection of ranibizumab in addition to the control group.The clinical efficacy,inflammation index levels,best corrected visual acuity,quality of life,and incidence of complications were compared between two groups.Results The total clinical effective rate of the observation group was 93.02%,higher than that of the control group(76.74%),the difference was statistically significant(P<0.05).After treatment,the levels of high-sensitivity C-reactive protein(hs-CRP),vascular endothelial growth factor(VEGF),and interleukin-6(IL-6)in the observation group were(6.05±0.09)mg/L,(35.04±7.44)ng/L,and(4.32±0.95)pg/mL,respectively,which were lower than those in the control group(7.33±0.12)mg/L,(48.55±9.68)ng/L,and(5.48±1.03)pg/mL,and the differences were statistically significant(P<0.05).The best corrected visual acuity of the observation group was(0.49±0.09),which was higher than that of the control group(0.34±0.06),and the difference was statistically significant(P<0.05).In the evaluation results of the World Health Organization quality of life scale-brief form questionnaire(WHOQOL-BREF),the scores for the psychological,physiological,environmental,and social relationship domains were(81.55±6.98)points,(70.12±6.12)points,(75.41±7.84)points,and(80.56±6.42)points,respectively,which were higher than those of the control group(72.39±5.47)points,(58.34±5.66)points,(64.93±5.99)points,and(71.55±5.37)points,and the differences were statistically significant(P<0.05).The incidence of complications in the observation group was 4.65%,which was lower than the control group's 20.93%,and the difference was statistically significant(P<0.05).Conclusion The combination of intravitreal injection of ranibizumab and vitrectomy for the treatment of VH has a definite effect,which can improve the best corrected visual acuity,reduce inflammatory reactions,reduce the occurrence of complications,and improve the quality of life.The research results of this article provide reference for the formulation of standardized treatment plans for VH in the later stage.
作者
李兵兵
张丽君
王敏
LI Bingbing;ZHANG Lijun;WANG Min(Department of Ophthalmology,Danjiangkou First Hospital,Danjiangkou Hubei 442700,China)
出处
《中国卫生标准管理》
2025年第14期151-155,共5页
China Health Standard Management
关键词
玻璃体积血
玻璃体切割术
最佳矫正视力
雷珠单抗玻璃体腔注射
并发症
生活质量
vitreous hemorrhage
vitrectomy
best corrected visual acuity
intravitreal injection of ranibizumab
complication
quality of life
